Search research articles
Contact Us
Filters
Showing results (581-590 of 686) with videos related to
Page
of 69
Sort By:
Journal of the National Cancer Institute
|
December 18, 2016
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
Grzegorz S Nowakowski, Kristie A Blum, Brad S Kahl, et al.
British Journal of Haematology
|
August 10, 2007
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy
Ruben Niesvizky, Tara Naib, Paul J Christos, et al.
AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science
|
July 2, 2019
Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent
Cindy Chen, Scott P Turner, Evan T Sholle, et al.
Bioinformatics (Oxford, England)
|
June 21, 2024
GENTANGLE: integrated computational design of gene entanglements
Jose Manuel Martí, Chloe Hsu, Charlotte Rochereau, et al.
Journal of Geriatric Oncology
|
April 21, 2018
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)
Michael Tallarico, Jared C Foster, Drew Seisler, et al.
Blood
|
January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
Jonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.
Journal of the National Cancer Institute
|
January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma
Stephen E Spurgeon, Brian G Till, Peter Martin, et al.
Blood
|
September 6, 2018
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma
Jia Ruan, Peter Martin, Paul Christos, et al.
Blood
|
September 2, 2020
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
Philippe Armand, Ann Janssens, Giuseppe Gritti, et al.
The Lancet. Haematology
|
May 30, 2020
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial
Gita Thanarajasingam, John P Leonard, Thomas E Witzig, et al.
Page
of 69
Search research articles
Search
Showing results (581-590 of 686) with videos related to
Sort By:
Page
of 69
Journal of the National Cancer Institute
|
December 18, 2016
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
Grzegorz S Nowakowski, Kristie A Blum, Brad S Kahl, et al.
British Journal of Haematology
|
August 10, 2007
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy
Ruben Niesvizky, Tara Naib, Paul J Christos, et al.
AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science
|
July 2, 2019
Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent
Cindy Chen, Scott P Turner, Evan T Sholle, et al.
Bioinformatics (Oxford, England)
|
June 21, 2024
GENTANGLE: integrated computational design of gene entanglements
Jose Manuel Martí, Chloe Hsu, Charlotte Rochereau, et al.
Journal of Geriatric Oncology
|
April 21, 2018
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)
Michael Tallarico, Jared C Foster, Drew Seisler, et al.
Blood
|
January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
Jonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.
Journal of the National Cancer Institute
|
January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma
Stephen E Spurgeon, Brian G Till, Peter Martin, et al.
Blood
|
September 6, 2018
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma
Jia Ruan, Peter Martin, Paul Christos, et al.
Blood
|
September 2, 2020
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
Philippe Armand, Ann Janssens, Giuseppe Gritti, et al.
The Lancet. Haematology
|
May 30, 2020
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial
Gita Thanarajasingam, John P Leonard, Thomas E Witzig, et al.
Page
of 69